Login / Signup

Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party.

Abdul-Hamid BazarbachiRama Al HamedMyriam LabopinKazimierz HalaburdaHelene LabussierePaolo BernasconiWilfried SchroyensVirginie GandemerNicolaas P M SchaapMichael LoschiPavel JindraJohn A SnowdenDepei WuBlandine GuffroyMontserrat RoviraSylvain P ChantepieXavier PoireLucia Lopez-CorralManos NikolousisMatteo PelosiniFabio CiceriFréderic BaronAli BazarbachiSelim CorbaciogluBipin N SavaniZinaida PericArnon NaglerEnric CarrerasMohamad Mohty
Published in: Bone marrow transplantation (2020)
Allogeneic hematopoietic cell transplantation (alloHCT) is a complex, potentially fatal therapy featuring a myriad of complications. Triggering event(s) of such complications vary significantly, but often a so-called "multi-organ failure" (MOF) is reported as the leading cause of death. The identification of the exact trigger of MOF is critical towards early and disease-specific intervention to improve outcome. We examined data from 202 alloHCT patients reported to have died of MOF from the EBMT registry aiming to determine their exact cause of death focusing on veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) due to its life-threatening, often difficult to capture yet preventable nature. We identified a total of 70 patients (35%) for whom VOD/SOS could be considered as trigger for MOF and leading cause of death, among which 48 (69%) were previously undiagnosed. Multivariate analysis highlighted history of hepatic comorbidity or gentuzumab use and disease status beyond CR1 as the only significant factors predictive of VOD/SOS incidence (OR = 6.6; p = 0.001 and OR = 3.3; p = 0.004 respectively). VOD/SOS-related MOF was widely under-reported, accounting for 27% of deaths attributed to MOF of unknown origin without a previous VOD/SOS diagnosis. Our results suggest most missed cases developed late VOD/SOS beyond 21 days post-alloHCT, highlighting the importance of the newly revised EBMT criteria.
Keyphrases